Business Context and Reporting Period
This Form 8-K Current Report was filed by Axsome Therapeutics, Inc. on June 16, 2017. The filing reports a corporate governance event: the expansion of the Board of Directors and the appointment of a new director.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance metrics.
Material Changes
- Board Expansion: The Board of Directors increased its size from four to five members.
- New Appointment: Myrtle Potter was appointed as a director, Chairman of the Compensation Committee, and a member of the Audit and Nominating and Corporate Governance Committees.
- Term: Ms. Potter serves as a Class II director, with a term expiring at the 2020 Annual Meeting of Shareholders.
Compensation and Governance Details
Ms. Potter will receive standard non-employee director compensation, with an annual cash retainer pro-rated for 2017. On June 16, 2017, she received two stock option grants:
- Initial Grant: Option to purchase 22,000 shares, vesting in three equal annual installments.
- Additional Grant: Option to purchase 8,197 shares, vesting one year from the grant date.
- Exercise Price: Both grants have an exercise price equal to the closing price of the Company's common stock on the date of grant.
The Board determined Ms. Potter to be an independent director. No other arrangements or understandings regarding her appointment exist.
Investor Verification Checklist
- Verify the pro-rated cash retainer amount in the Company's 2017 proxy statement filed on April 28, 2017.
- Confirm the closing stock price on June 16, 2017, to determine the exercise price of the granted options.
- Review the attached press release (Exhibit 99.1) for additional context on the appointment.
- Note that the information in Item 7.01 is not deemed "filed" under Section 18 of the Exchange Act.